According to latest Symphony Health Solutions Rx data Zubsolv tablets market share (4-week rolling average) reached 6.16% (6.19%). The total number of Zubsolv tablets sold week 36 (35) declined to 318,278 (349,737) from last week. Zubsolv prescriptions (TRx) recorded a market share (4-week rolling average) of 6.21% (6.24%), totaling 11,575 (12,395) prescriptions during the week. The overall market (buprenorphine/naloxone products) showed a y/y growth rate of 6.7% (6.6%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 6.1% (5.9%) (4-week rolling average).